BIO-RAD LABORATORIES, INC. 8-K

What Happened
Bio‑Rad Laboratories filed an 8‑K on February 19, 2026 to provide an update to the “Investment in Sartorius AG” disclosure in its Form 10‑K (filed February 13, 2026). The update restates key financial results that Sartorius AG disclosed on February 16, 2026 for the year ended December 31, 2025. Bio‑Rad notes these figures come from Sartorius’ audited consolidated financial statements prepared under IFRS and disclaims responsibility for any errors in Sartorius’ public disclosures.

Key Details

• Sartorius AG balance sheet (as of Dec 31, 2025): Current assets €1,766.2m; Non‑current assets €7,951.1m; Current liabilities €1,967.4m; Non‑current liabilities €3,882.6m; Equity €3,867.2m.
• Sartorius AG income statement (year ended Dec 31, 2025): Sales revenue €3,538.1m; Gross profit €1,636.7m; EBIT €542.6m; Net profit €230.4m.
• Cash flows (2025): Operating activities €837.0m; Investing activities (€513.7m); Financing activities (€591.4m).
• Source/notes: Figures come from Sartorius AG’s 2025 consolidated financial statements (IFRS); Bio‑Rad references Sartorius’ 2025 Annual Report and states the Sartorius website is not incorporated by reference into Bio‑Rad’s filing.

Why It Matters
This update provides investors with the specific full‑year 2025 financial metrics for Sartorius AG that Bio‑Rad referenced in its Form 10‑K investment disclosure. Those numbers help shareholders assess the size, profitability, and cash‑flow profile of Sartorius — a company in which Bio‑Rad holds an investment — and can affect how investors view the value and risk of Bio‑Rad’s non‑operating holdings. Bio‑Rad’s 8‑K is informational and reiterates that the primary source is Sartorius’ own audited reports.